Gifford Bioscience contributes its receptor pharmacology expertise to the study of the effect of methylone as a rapid-acting neuroplastogen, with greater specificity than MDMA. This bolsters methylone’s potential use in the treatment of PTSD and other neuropsychiatric disorders.
Read the publication paper here.
